International Journal of Colorectal Disease

, Volume 19, Issue 1, pp 1–11 | Cite as

Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer

  • Milind Rao
  • Wenxuan Yang
  • Alexander M. Seifalian
  • Marc C. Winslet
Review

Abstract

Background

Cyclooxygenase (COX) is the rate-limiting enzyme in the synthesis of prostaglandins. It exists in two isoforms: COX-1 which is constitutively expressed and COX-2 which is an inducible form activated by a variety of cytokines during inflammation.

Discussion

Interest in this enzyme arose in the early 1990s when, following epidemiological studies, aspirin (which is a COX inhibitor) was found to reduce the risk of colorectal cancer. Since then various studies to decipher the mechanisms by which COX reduces the development of colorectal cancer have been undertaken. One of the mechanisms being studied is its role in the angiogenesis of colorectal cancer. Angiogenesis of its own has been well established as a key factor in the development of tumours. Agents that specifically inhibit COX-2 are now in clinical development and have been licensed to be used in patients with familial adenomatosis polyposis.

Conclusion

What needs to be determined is whether the antiangiogenic effects of COX-2 inhibitors can be used in the prevention and/or treatment of colorectal cancer and its metastases.

Keywords

Colorectal cancer Angiogenesis Cyclooxygenase Cyclooxygenase inhibitor 

References

  1. 1.
    Huang A, McCall JM, Weston MD, Mathur P, Quinn H, Henderson DC, et al (2002) Phase I study of percutaneous cryotherapy for colorectal liver metastasis. Br J Surg 89:303–310CrossRefPubMedGoogle Scholar
  2. 2.
    Fosslien E (2001) Review: Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 31:325–348PubMedGoogle Scholar
  3. 3.
    Le Querrec A, Duval D, Tobelem G (1993) Tumour angiogenesis. Baillieres Clin Haematol 6:711–730PubMedGoogle Scholar
  4. 4.
    Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188PubMedGoogle Scholar
  5. 5.
    Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, et al (2000) Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6:4064–4068PubMedGoogle Scholar
  6. 6.
    Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, et al (1999) Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 79:1469–1477PubMedGoogle Scholar
  7. 7.
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241–2416PubMedGoogle Scholar
  8. 8.
    Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609–614PubMedGoogle Scholar
  9. 9.
    Smalley WE, DuBois RN (1997) Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 39:1–20PubMedGoogle Scholar
  10. 10.
    Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593–1596Google Scholar
  11. 11.
    Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53:1322–1327PubMedGoogle Scholar
  12. 12.
    DuBois RN (2000) Review article: cyclooxygenase-a target for colon cancer prevention. Aliment Pharmacol Ther 14 [Suppl 1]:64–67Google Scholar
  13. 13.
    Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK (2001) Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 91:894–899Google Scholar
  14. 14.
    Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, et al (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60:293–297PubMedGoogle Scholar
  15. 15.
    Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedGoogle Scholar
  16. 16.
    Gately S (2000) The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 19:19–27PubMedGoogle Scholar
  17. 17.
    Li Z, Shimada Y, Uchida S, Maeda M, Kawabe A, Mori A, et al (2000) TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol 17:453–460PubMedGoogle Scholar
  18. 18.
    Matsushita M, Matsuzaki K, Date M, Watanabe T, Shibano K, Nakagawa T, et al (1999) Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development. Br J Cancer 80:194–205CrossRefPubMedGoogle Scholar
  19. 19.
    Xiong B, Gong LL, Zhang F, Hu MB, Yuan HY (2002) TGF beta (1) expression and angiogenesis in colorectal cancer tissue. World J Gastroenterol 8:496–498PubMedGoogle Scholar
  20. 20.
    Schulze-Osthoff K, Risau W, Vollmer E, Sorg C (1990) In situ detection of basic fibroblast growth factor by highly specific antibodies. Am J Pathol 137:85–92PubMedGoogle Scholar
  21. 21.
    Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS (2000) Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19:4611–4620CrossRefPubMedGoogle Scholar
  22. 22.
    Vane JR, Botting RMr (2001) Therapeutic roles of selective COX-2 inhibitors. Harvey, LondonGoogle Scholar
  23. 23.
    Trifan OC, Smith RM, Thompson BD, Hla T (1999) Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism. J Biol Chem 274:34141–34147CrossRefPubMedGoogle Scholar
  24. 24.
    Luk GD (1996) Prevention of gastrointestinal cancer-the potential role of NSAIDs in colorectal cancer. Schweiz Med Wochenschr 126:801–812PubMedGoogle Scholar
  25. 25.
    Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, et al (1996) Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A 93:4816–8620CrossRefPubMedGoogle Scholar
  26. 26.
    Gustafson-Svard C, Lilja I, Hallbook O, Sjodahl R (1996) Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 38:79–84PubMedGoogle Scholar
  27. 27.
    DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD (1996) G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 56:733–737PubMedGoogle Scholar
  28. 28.
    Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al (1995) Expression of cyclooxygenase-1 and −2 in human colorectal cancer. Cancer Res 55:3785–9378PubMedGoogle Scholar
  29. 29.
    Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al (1997) Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99:2254–2259PubMedGoogle Scholar
  30. 30.
    Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493–501PubMedGoogle Scholar
  31. 31.
    Crew TE, Elder DJ, Paraskeva C (2000) A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis 21:69–77CrossRefPubMedGoogle Scholar
  32. 32.
    Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58:362–636PubMedGoogle Scholar
  33. 33.
    Li M, Wu X, Xu XC (2001) Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 7:1010–1016PubMedGoogle Scholar
  34. 34.
    Elder DJ, Halton DE, Crew TE, Paraskeva C (2000) Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 86:553–560Google Scholar
  35. 35.
    Richter M, Weiss M, Weinberger I, Furstenberger G, Marian B (2001) Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 22:17–25CrossRefPubMedGoogle Scholar
  36. 36.
    Erickson BA, Longo WE, Panesar N, Mazuski JE, Kaminski DL (1999) The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 81:101–107CrossRefPubMedGoogle Scholar
  37. 37.
    Fukutake M, Nakatsugi S, Isoi T, Takahashi M, Ohta T, Mamiya S, et al (1998) Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 19:1939–19342CrossRefPubMedGoogle Scholar
  38. 38.
    Ichikawa Y, Ishikawa T, Tanaka K, Togo S, Shimada H (2001) [Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy]. Nippon Geka Gakkai Zasshi 102:376–380PubMedGoogle Scholar
  39. 39.
    Tsujii M, Kawano S, DuBois RN (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 94:3336–3340PubMedGoogle Scholar
  40. 40.
    Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306–1311PubMedGoogle Scholar
  41. 41.
    Hao X, Bishop AE, Wallace M, Wang H, Willcocks TC, Maclouf J, et al (1999) Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 187:295–301CrossRefPubMedGoogle Scholar
  42. 42.
    Zhang H, Sun XF (2002) Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 97:1037–1041CrossRefPubMedGoogle Scholar
  43. 43.
    Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705–716PubMedGoogle Scholar
  44. 44.
    Masferrer JL, Koki A, Seibert K (1999) COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci 889:84–86PubMedGoogle Scholar
  45. 45.
    Onn A, Tseng JE, Herbst RS (2001) Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy. Clin Cancer Res 7:3311–3313PubMedGoogle Scholar
  46. 46.
    Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282:1254–1257PubMedGoogle Scholar
  47. 47.
    Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, et al (2000) Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 83:324–328Google Scholar
  48. 48.
    Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, et al (1998) Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 58:4823–4826PubMedGoogle Scholar
  49. 49.
    Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105:1589–1594PubMedGoogle Scholar
  50. 50.
    Dormond O, Foletti A, Paroz C, Ruegg C (2001) NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 7:1041–1047CrossRefPubMedGoogle Scholar
  51. 51.
    Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, et al (2001) Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121:1339–1347PubMedGoogle Scholar
  52. 52.
    Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, et al (2001) Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3:53–61CrossRefPubMedGoogle Scholar
  53. 53.
    Form DM, Auerbach R (1983) PGE2 and angiogenesis. Proc Soc Exp Biol Med 172:214–218PubMedGoogle Scholar
  54. 54.
    Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S (1995) Expression of prostaglandin G/H synthase-1 and −2 protein in human colon cancer. Cancer Res 55:2556–2559PubMedGoogle Scholar
  55. 55.
    Levy GN (1997) Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 11:234–247PubMedGoogle Scholar
  56. 56.
    Bing RJ, Miyataka M, Rich KA, Hanson N, Wang X, Slosser HD, et al (2001) Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer. Clin Cancer Res 7:3385–3392PubMedGoogle Scholar
  57. 57.
    Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ (1999) Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59:4574–4577PubMedGoogle Scholar
  58. 58.
    Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5:1418–1423CrossRefPubMedGoogle Scholar
  59. 59.
    Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252–266CrossRefPubMedGoogle Scholar
  60. 60.
    Prescott SM, Fitzpatrick FA (2000) Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470:M69–M78CrossRefPubMedGoogle Scholar
  61. 61.
    Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN (2000) Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 275:33951–3396CrossRefPubMedGoogle Scholar
  62. 62.
    Dicker AP, Williams TL, Grant DS (2001) Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 24:438–442Google Scholar
  63. 63.
    Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62:625–631PubMedGoogle Scholar
  64. 64.
    Simmons DL, Botting RM, Robertson PM, Madsen ML, Vane JR (1999) Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc Natl Acad Sci U S A 96:3275–3280CrossRefPubMedGoogle Scholar
  65. 65.
    Barnes CJ, Cameron IL, Hardman WE, Lee M (1998) Non-steroidol anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Br J Cancer 77:573–580PubMedGoogle Scholar
  66. 66.
    Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, et al (1998) Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 19:2195–2199CrossRefPubMedGoogle Scholar
  67. 67.
    Yu HG, Huang JA, Yang YN, Huang H, Luo HS, Yu JP, et al (2002) The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest 32:838–846CrossRefPubMedGoogle Scholar
  68. 68.
    Murphy VJ, Yang Z, Rorison KA, Baldwin GS (1998) Cyclooxygenase-2-selective antagonists do not inhibit growth of colorectal carcinoma cell lines. Cancer Lett 122:25–30CrossRefPubMedGoogle Scholar
  69. 69.
    Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN (2000) Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 60:6045–6051PubMedGoogle Scholar
  70. 70.
    McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96:272–277PubMedGoogle Scholar
  71. 71.
    Whittle BJ (2000) COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors. Gut 47:320–325CrossRefPubMedGoogle Scholar
  72. 72.
    Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada T, Kitayama J, et al (1999) Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer 81:1274–1279Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Milind Rao
    • 1
  • Wenxuan Yang
    • 1
  • Alexander M. Seifalian
    • 1
  • Marc C. Winslet
    • 1
  1. 1.University Department of Surgery, Royal Free and University College Medical School, Royal Free HospitalUniversity College LondonLondonUK

Personalised recommendations